cancer
Herve Affagard, Chief Executive Officer at MaaT Pharma, gives us an update on the clinical trials (Maat013 and Maat033) and describes the vision of the company for the future of the…
Collaboration joins MD Anderson's expertise and capabilities with Fed Bio's proprietary ACT bacterial cell therapy platform to design and manufacture a complex, synthetic microbiome-based therapy
The findings of a recent study tie the gut microbiota to immune surveillance of ovarian cancer and may inform new treatment approaches.
The agreement will aid in the understanding of the microbiome in human disease.
The DGCCRF has announced that the use of the word “probiotic” can be allowed on the label of dietary supplements, as well as the health claim “contributes to the balance…
Fabio Grassi, Founder at MV BioTherapeutics SA, discussed how to understand the mechanisms of action for microbiome contributions to cancer therapeutic response in patients.
First patient to be administered Oncobax® AK, a live bacterial product based on a specific strain found in the gut microbiota, at Institut de Cancérologie Strasbourg Europe (ICANS) in Strasbourg,…
The OncobiotaLUNG assay is the first blood microbiome-driven liquid biopsy with proven effectiveness, including identifying cancer in its earliest stages
The findings of a new research suggest that dietary and antibacterial strategies may help to prevent neutropenia-related fever after cancer therapy.
The findings of a recent study suggest that DNA damage-inducing microbial metabolites such as indolimines play a role in the development of colorectal cancer.
